Ironwood Pharma to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals (NASDAQ:IRWD) will present new data at the 2023 NASPGHAN Annual Meeting, demonstrating that linaclotide decreased the use of rescue medications in children and adolescents with functional constipation. This builds on previously announced data from the company's pivotal Phase III trial, which led to FDA approval of linaclotide for the treatment of functional constipation in this pediatric population.
October 05, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ironwood Pharmaceuticals will present new data on linaclotide, reinforcing its effectiveness in treating functional constipation in children. This could potentially boost the company's reputation and sales.
The presentation of new data on linaclotide at a major conference could potentially boost the visibility and reputation of Ironwood Pharmaceuticals. This, coupled with the fact that the drug has already received FDA approval, could lead to increased sales and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100